Cat. No. 3660
Alternative Name: BMS614
Chemical Name: 4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-
Biological ActivityNeutral retinoic acid receptor (RAR) α-selective antagonist (Ki = 2.5 nM). Displays no significant effect on nuclear receptor corepressor (NCoR) binding; moderately decreases SMRT binding to RAR. Antagonizes agonist-induced coactivator (CoA) recruitment.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Germain et al (2009) Differential action on coregulator interaction defines retinoid agonists and neutral antagonists. Chem.Biol. 16 479. PMID: 19477412.
Gehin et al (1999) Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem.Biol. 6 519. PMID: 10421757.
Schoenermark et al (1999) Retinoid-mediated suppression of tumor invasion and matrix metalloproteinase synthesis. Ann.N.Y.Acad.Sci. 30 878.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for BMS 195614 include:
Flamini et al (2014) Retinoic acid reduces migration of human breast cancer cells: role of retinoic acid receptor beta. J Cell Mol Med 18 1113. PMID: 24720764.
Johansson et al (2013) Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun 4 2175. PMID: 23868472.
Do you know of a great paper that uses BMS 195614 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: BMS 195614, supplier, BMS195614, retinoic, acid, receptor, RAR, alpha, α, RARa, antagonists, neutral, selective, BMS614, Tocris Bioscience, Retinoic Acid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonistSR 9009
Rev-Erbα/β agonistSR 9238
Potent and selective LXR inverse agonist
October 30 - November 3, 2016
Boston, MA, USA